DK3551617T3 - Sammensætninger og fremgangsmåder relateret til pyridinodylpiperidin-5-HT1F-agonister - Google Patents

Sammensætninger og fremgangsmåder relateret til pyridinodylpiperidin-5-HT1F-agonister Download PDF

Info

Publication number: DK3551617T3
Authority: DK; Denmark
Prior art keywords: pyridinodylpiperidine; compositions; methods related; ht1f agonists; ht1f
Prior art date: 2016-12-06

Application number

DK17829372.6T

Other languages

English (en)

Inventor

Brigida Allieri

Paul Fagan

Emma Sharp

Raymond D Skwierczynski

Original Assignee

Colucid Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-06

Filing date

2017-12-05

Publication date

2021-09-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60972336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3551617(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-12-05 Application filed by Colucid Pharmaceuticals Inc filed Critical Colucid Pharmaceuticals Inc

2021-09-13 Application granted granted Critical

2021-09-13 Publication of DK3551617T3 publication Critical patent/DK3551617T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK17829372.6T 2016-12-06 2017-12-05 Sammensætninger og fremgangsmåder relateret til pyridinodylpiperidin-5-HT1F-agonister DK3551617T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662430662P	2016-12-06	2016-12-06
PCT/US2017/064652 WO2018106657A1 (en)	2016-12-06	2017-12-05	Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists

Publications (1)

Publication Number	Publication Date
DK3551617T3 true DK3551617T3 (da)	2021-09-13

Family

ID=60972336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17829372.6T DK3551617T3 (da)	2016-12-06	2017-12-05	Sammensætninger og fremgangsmåder relateret til pyridinodylpiperidin-5-HT1F-agonister

Country Status (38)

Country	Link
US (1)	US11053214B2 (da)
EP (1)	EP3551617B1 (da)
JP (4)	JP2020500936A (da)
KR (3)	KR20230008257A (da)
CN (3)	CN110291079A (da)
AU (1)	AU2017373784B2 (da)
BR (1)	BR112019010934A2 (da)
CA (1)	CA3043772C (da)
CL (1)	CL2019001426A1 (da)
CO (1)	CO2019005290A2 (da)
CR (1)	CR20190251A (da)
CY (1)	CY1124540T1 (da)
DK (1)	DK3551617T3 (da)
DO (1)	DOP2019000139A (da)
EA (1)	EA201991112A1 (da)
EC (1)	ECSP19040190A (da)
ES (1)	ES2889476T3 (da)
HR (1)	HRP20211557T1 (da)
HU (1)	HUE056820T2 (da)
IL (1)	IL266598B2 (da)
JO (1)	JOP20190129B1 (da)
LT (1)	LT3551617T (da)
MA (1)	MA52920B1 (da)
MD (1)	MD3551617T2 (da)
MX (2)	MX388091B (da)
MY (1)	MY196855A (da)
NZ (1)	NZ752906A (da)
PE (2)	PE20191134A1 (da)
PH (1)	PH12019501252B1 (da)
PL (1)	PL3551617T3 (da)
PT (1)	PT3551617T (da)
RS (1)	RS62415B1 (da)
SI (1)	SI3551617T1 (da)
TN (1)	TN2019000174A1 (da)
TW (1)	TWI671290B (da)
UA (1)	UA124433C2 (da)
WO (1)	WO2018106657A1 (da)
ZA (1)	ZA201903449B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5727457B2 (ja)	2009-04-02	2015-06-03	コルーシッドファーマシューティカルズ，インコーポレイテッド	２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
TWI826514B (zh)	2018-09-04	2023-12-21	美商美國禮來大藥廠	用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
AR119319A1 (es)	2019-07-09	2021-12-09	Lilly Co Eli	Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CN111004214B (zh) *	2019-11-22	2021-06-08	广东东阳光药业有限公司	吡啶酰基哌啶衍生物及其用途
US12271057B1 (en)	2019-12-20	2025-04-08	The Uab Research Foundation	Chromatic aberration tuning ophthalmic corrector lens methods
JP2024517874A (ja)	2021-05-07	2024-04-23	イーライリリーアンドカンパニー	２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の味マスキングされた組成物、及びそれを含む経口崩壊錠剤
CN116270505A (zh) *	2021-12-20	2023-06-23	南京科默生物医药有限公司	含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
TWI263497B (en) *	2002-03-29	2006-10-11	Lilly Co Eli	Pyridinoylpiperidines as 5-HT1F agonists
US20060178349A1 (en) *	2005-01-24	2006-08-10	Pozen Inc.	Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
JP5727457B2 (ja)	2009-04-02	2015-06-03	コルーシッドファーマシューティカルズ，インコーポレイテッド	２，４，６−トリフルオロ−ｎ−［６−（１−メチル−ピペリジン−４−カルボニル）−ピリジン−２−イル］−ベンズアミドの組成物
WO2011123654A1 (en) *	2010-04-02	2011-10-06	Colucid Pharmaceuticals, Inc.	Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
WO2012163365A1 (en)	2011-06-01	2012-12-06	Concit Pharma Aps	Combinations of serotonin receptor agonists for treatment of movement disorders
WO2018010345A1 (zh)	2016-07-15	2018-01-18	杭州领业医药科技有限公司	一种受体激动剂的晶型及其制备方法和药物组合物
TWI754772B (zh)	2017-09-06	2022-02-11	美商美國禮來大藥廠	用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

2017
- 2017-12-05 PT PT17829372T patent/PT3551617T/pt unknown
- 2017-12-05 PE PE2019001167A patent/PE20191134A1/es unknown
- 2017-12-05 JO JOP/2019/0129A patent/JOP20190129B1/ar active
- 2017-12-05 IL IL266598A patent/IL266598B2/en unknown
- 2017-12-05 PE PE2023002466A patent/PE20241297A1/es unknown
- 2017-12-05 HR HRP20211557TT patent/HRP20211557T1/hr unknown
- 2017-12-05 CN CN201780075750.7A patent/CN110291079A/zh active Pending
- 2017-12-05 US US16/467,208 patent/US11053214B2/en active Active
- 2017-12-05 MY MYPI2019003189A patent/MY196855A/en unknown
- 2017-12-05 EA EA201991112A patent/EA201991112A1/ru unknown
- 2017-12-05 JP JP2019551251A patent/JP2020500936A/ja active Pending
- 2017-12-05 DK DK17829372.6T patent/DK3551617T3/da active
- 2017-12-05 WO PCT/US2017/064652 patent/WO2018106657A1/en active Application Filing
- 2017-12-05 NZ NZ752906A patent/NZ752906A/en unknown
- 2017-12-05 TN TNP/2019/000174A patent/TN2019000174A1/en unknown
- 2017-12-05 LT LTEPPCT/US2017/064652T patent/LT3551617T/lt unknown
- 2017-12-05 MD MDE20191169T patent/MD3551617T2/ro unknown
- 2017-12-05 PH PH1/2019/501252A patent/PH12019501252B1/en unknown
- 2017-12-05 EP EP17829372.6A patent/EP3551617B1/en active Active
- 2017-12-05 KR KR1020227046438A patent/KR20230008257A/ko not_active Ceased
- 2017-12-05 RS RS20211233A patent/RS62415B1/sr unknown
- 2017-12-05 SI SI201730881T patent/SI3551617T1/sl unknown
- 2017-12-05 HU HUE17829372A patent/HUE056820T2/hu unknown
- 2017-12-05 MX MX2019006520A patent/MX388091B/es unknown
- 2017-12-05 CN CN202210944298.6A patent/CN115385893A/zh active Pending
- 2017-12-05 UA UAA201905483A patent/UA124433C2/uk unknown
- 2017-12-05 KR KR1020197016255A patent/KR20190075130A/ko not_active Ceased
- 2017-12-05 CN CN202210944373.9A patent/CN115385894A/zh active Pending
- 2017-12-05 KR KR1020217025499A patent/KR20210102497A/ko not_active Ceased
- 2017-12-05 ES ES17829372T patent/ES2889476T3/es active Active
- 2017-12-05 MA MA52920A patent/MA52920B1/fr unknown
- 2017-12-05 TW TW106142535A patent/TWI671290B/zh active
- 2017-12-05 CR CR20190251A patent/CR20190251A/es unknown
- 2017-12-05 BR BR112019010934A patent/BR112019010934A2/pt not_active Application Discontinuation
- 2017-12-05 PL PL17829372T patent/PL3551617T3/pl unknown
- 2017-12-05 MX MX2021014139A patent/MX392547B/es unknown
- 2017-12-05 AU AU2017373784A patent/AU2017373784B2/en active Active
- 2017-12-05 CA CA3043772A patent/CA3043772C/en active Active
2019
- 2019-05-23 CO CONC2019/0005290A patent/CO2019005290A2/es unknown
- 2019-05-27 CL CL2019001426A patent/CL2019001426A1/es unknown
- 2019-05-30 DO DO2019000139A patent/DOP2019000139A/es unknown
- 2019-05-30 ZA ZA2019/03449A patent/ZA201903449B/en unknown
- 2019-06-06 EC ECSENADI201940190A patent/ECSP19040190A/es unknown
2021
- 2021-09-22 JP JP2021153729A patent/JP2022000451A/ja active Pending
- 2021-10-05 CY CY20211100864T patent/CY1124540T1/el unknown
2023
- 2023-06-26 JP JP2023104019A patent/JP7561240B2/ja active Active
2024
- 2024-09-20 JP JP2024163884A patent/JP2024178323A/ja active Pending

Also Published As

Publication number	Publication date
BR112019010934A2 (pt)	2019-10-01
CL2019001426A1 (es)	2019-10-11
MX392547B (es)	2025-03-24
JOP20190129A1 (ar)	2019-05-29
MD3551617T2 (ro)	2021-12-31
AU2017373784B2 (en)	2020-04-23
KR20210102497A (ko)	2021-08-19
MA52920B1 (fr)	2021-11-30
ZA201903449B (en)	2021-02-24
TW201833097A (zh)	2018-09-16
CN115385893A (zh)	2022-11-25
US20200087279A1 (en)	2020-03-19
KR20190075130A (ko)	2019-06-28
PH12019501252A1 (en)	2019-12-02
ECSP19040190A (es)	2019-08-30
WO2018106657A1 (en)	2018-06-14
CN110291079A (zh)	2019-09-27
NZ752906A (en)	2021-07-30
EP3551617B1 (en)	2021-08-11
PH12019501252B1 (en)	2024-05-24
JP2020500936A (ja)	2020-01-16
CA3043772A1 (en)	2018-06-14
JP2022000451A (ja)	2022-01-04
IL266598B1 (en)	2024-01-01
EA201991112A1 (ru)	2019-10-31
PT3551617T (pt)	2021-10-04
PE20191134A1 (es)	2019-09-02
MX2021014139A (es)	2022-05-24
IL266598A (en)	2019-07-31
MX2019006520A (es)	2019-08-21
CO2019005290A2 (es)	2019-05-31
UA124433C2 (uk)	2021-09-15
HUE056820T2 (hu)	2022-03-28
CN115385894A (zh)	2022-11-25
PE20241297A1 (es)	2024-06-24
JP7561240B2 (ja)	2024-10-03
CA3043772C (en)	2022-06-07
JP2023123678A (ja)	2023-09-05
JP2024178323A (ja)	2024-12-24
KR20230008257A (ko)	2023-01-13
AU2017373784A1 (en)	2019-05-16
IL266598B2 (en)	2024-05-01
LT3551617T (lt)	2021-10-11
DOP2019000139A (es)	2019-08-15
EP3551617A1 (en)	2019-10-16
MA52920A (fr)	2021-04-28
SI3551617T1 (sl)	2021-11-30
CR20190251A (es)	2019-08-26
JOP20190129B1 (ar)	2023-03-28
RS62415B1 (sr)	2021-10-29
MX388091B (es)	2025-03-19
TN2019000174A1 (en)	2020-10-05
PL3551617T3 (pl)	2021-12-20
HRP20211557T1 (hr)	2022-01-07
ES2889476T3 (es)	2022-01-12
MY196855A (en)	2023-05-05
CY1124540T1 (el)	2022-07-22
TWI671290B (zh)	2019-09-11
US11053214B2 (en)	2021-07-06

Publication	Publication Date	Title
HK1257295A1 (zh)	2019-10-18	用於免疫腫瘤學的組合物和方法
DK3234133T3 (da)	2021-02-08	Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3443009T3 (da)	2021-12-13	Anti-tim-3-antistoffer og sammensætninger
DK3145493T3 (da)	2022-10-31	Fremgangsmåder og sammensætninger vedrørende exosomer
DK3316909T3 (da)	2023-11-13	Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3557998T3 (da)	2023-11-20	Sammensætninger, kompositioner og anvendelsesmetoder
DK3325669T3 (da)	2023-10-09	Sammensætninger og fremgangsmåder til RNA-analyse
DK3495023T3 (da)	2020-07-20	Semifluorerede forbindelser og sammensætninger deraf
DK3317284T3 (da)	2020-01-13	Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3092256T3 (da)	2022-06-20	Forbindelser og sammensætninger til immunterapi
DK3240895T3 (da)	2022-04-11	Sammensætninger og fremgangsmåder til proteinglykosylering
DK3169741T3 (da)	2023-01-09	Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK3169733T3 (da)	2024-12-16	Forbedrede bindemiddelsammensætninger og anvendelser deraf
KR20180084891A (ko)	2018-07-25	구조 조성물 및 방법
DK3108009T3 (da)	2021-06-07	Fremgangsmåder og sammensætninger til DNA-profilering
DK3125927T3 (da)	2021-04-19	Fremgangsmåder og sammensætninger til immunmodulering
DK2961831T3 (da)	2020-09-07	Sammensætninger og fremgangsmåder til immunterapi
DK3008168T3 (da)	2020-05-04	Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3015526T3 (da)	2021-01-18	Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3394065T3 (da)	2021-05-31	Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3551617T3 (da)	2021-09-13	Sammensætninger og fremgangsmåder relateret til pyridinodylpiperidin-5-HT1F-agonister
DK3233192T3 (da)	2021-07-19	Sammensætninger og fremgangsmåder til målrettet cytokinindgivelse
DK3393655T3 (da)	2021-03-15	Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3194564T3 (da)	2020-10-19	Trichodermasammensætninger og anvendelsesfremgangsmåder